For an extended time, IBT has consulted with the US Food and Drug Administration (FDA) on how the company’s planned Phase III study should be designed. IBT announced on 5/19/19 that the FDA has... read more
For an extended time, IBT has consulted with the US Food and Drug Administration (FDA) on how the company’s planned Phase III study should be designed. IBT announced on 5/19/19 that the FDA has... read more
A National Leader in Healthcare Research Heads Operations and Delivery Team
Columbia, MD, May 20, 2019 – Health Analytics, LLC, a leading provider... read more
On 5/20/19 Syncona Ltd ("Syncona") announced the foundation of Quell Therapeutics (Quell), a new cell therapy company, with a £35 million ($43 million) commitment in a Series A financing of which... read more
